Three years ago, after Merck Serono pulled the plug on its operations in Switzerland, a team of 8 neurodegeneration specialists used the shutdown as an opportunity to start their own biotech spinout, dubbed Asceneuron. And now they've gathered a substantial $30.6 million round to fund their drive into the clinic with a new drug candidate for Alzheimer's disease.
A little more than a year after Deciphera CEO Mike Taylor set up an office for the biotech in the Boston area, the cancer drug developer has rounded up a whopping $75 million B round to make a clinical push for its top cancer drug candidates.
Intarcia Therapeutics is rolling toward an FDA application with its long-acting diabetes treatment, but despite the ready availability of IPO cash for drug developers, the company is content to stay private for now.
The biotech IPO window is still wide open and ready for new business, especially if it relates to a hot new tech like gene therapy. RegenX Bio proved that point today, raising $138 million from the sale of 6.3 million shares at $22 a pop.
Less than two years after OrbiMed unleashed its last big biotech fund, the venture group is going back to the well to piece together an even bigger, $950 million cache of cash.
Third Rock Ventures startup Nurix is lending its drug-development prowess to Celgene in exchange for $150 million up front and much more down the line, collaborating on potential treatments for cancer and immunology.
Under-the-radar biotech startup Alector raised $32 million in Series C funds to support its early-stage work in neurodegenerative disease, recruiting some high-profile investors as it develops a novel approach to brain-destroying disorders.
NantCell, one of billionaire entrepreneur Patrick Soon-Shiong's biotech ventures, raised $100 million in equity cash, moving forward with some in-licensed immuno-oncology treatments.
Gene therapy biotech AveXis raised $65 million in Series D cash to advance a potential one-time treatment for the rare spinal muscular atrophy, a debilitating disease with no approved therapies.
Selecta Biosciences is taking another carefully planned step down the biotech path it set for itself, raking in $38 million in fresh venture cash from some prominent investors--including its close collaborator Sanofi--and paving the way through a key mid-stage study of its lead program.